Highly Efficient Coupling of Nanolight Emitters to a Ultra-wide Tunable Nanofibre Cavity

Solid-state microcavities combining ultra-small mode volume, wide-range resonance frequency tuning, as well as lossless coupling to a single mode fibre are integral tools for nanophotonics and quantum networks. We developed an integrated system providing all of these three indispensable properties. It consists of a nanofibre Bragg cavity (NFBC) with the mode volume of under 1 micro cubic meter and repeatable tuning capability over more than 20 nm at visible wavelengths. In order to demonstrate quantum light-matter interaction, we establish coupling of quantum dots to our tunable NFBC and achieve an emission enhancement by a factor of 2.7.Comment: 19 pages, 8 figures, including Supporting Information (5 pages, 4 figures), accepted for SCIENTIFC REPORT

Non-contact detection of nanoscale structures using optical nanofiber

The detection of nanoscale structure/material property in a wide observation area is becoming very important in various application fields. However, it is difficult to utilize current optical technologies. Toward the realization of novel alternative, we have investigated a new optical sensing method using an optical nanofiber. When the nanofiber vertically approached a glass prism with a partial gold film, the material differences between the glass and the gold were detected as a transmittance difference of 6% with a vertical resolution of 9.6 nm. The nanofiber was also scanned 100 nm above an artificial small protruding object with a width of 240 nm. The object was detected with a horizontal resolution of 630 nm, which was less than the wavelength of the probe light

Microwave spectroscopy of the PBr radical in the X (3)Sigma(-) state.

publishe

Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor A case report

Rationale: Tumor-induced osteomalacia (TIO) is curable by tumor resection, but detection of the tumor can be challenging. Overproduction of fibroblast growth factor 23 (FGF23) by the tumor causes hypophosphatemia and consequently induces inappropriate bone turnover. Conventionally oral phosphate supplementation was the only treatment for TIO, but had risks of hypercalciuria and nephrocalcinosis. Burosumab, a human monoclonal anti-FGF23 antibody, was recently post-marketed in Japan against for FGF23-related hypophosphatemia. Herein, we present a case of TIO with undetectable tumor that was successfully treated with burosumab. Patient concerns: A 47-year-old woman was forced to use a wheelchair because of pain in both feet. Diagnosis: Laboratory findings showed hypophosphatemia, elevated bone markers, and high serum FGF23 without renal tubular defects. Imaging studies revealed bone atrophy in the feet, decreased bone density, and multiple pseudofractures in the talar, sacral, and L5 vertebral regions. After excluding drug-induced and hereditary osteomalacia, we diagnosed her as TIO. Interventions: Comprehensive imaging studies and stepwise venous sampling failed to localize the tumor, and we started to administer subcutaneous burosumab. Outcomes: After administration of burosumab, her serum phosphate was normalized without phosphate supplementation within 2 months. Improvement of pseudofractures, relief of pain evaluated by a visual analog scale, and normalization of bone biomarkers were observed. The patient was able to stand by herself after 6 months administration of burosumab. Lessons: This is the first report in clinical practice to demonstrate favorable effects of burosumab, including not only normalization of serum phosphate but also improvements of pseudofractures and subjective pain, in a patient with TIO and undetectable tumor